ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Continuing angiotensin system blockade using transition to angiotensin receptor-neprilysin inhibitor therapy for adults with heart failure with reduced ejection fraction

Continuing angiotensin system blockade using transition to angiotensin receptor-neprilysin inhibitor therapy for adults with heart failure with reduced ejection fraction
  • This algorithm is for use in patients who are already taking an angiotensin system blocker and is intended for use in conjunction with additional UpToDate content on initial management of HFrEF in adults. Refer to UpToDate topics on pharmacologic management of HFrEF in adults for additional details of our approach to treatment and the overall efficacy of these agents.
  • Initial long-term management of HFrEF includes combined treatment with diuretic therapy (as needed) plus an angiotensin system blocker (ARNI, ACE inhibitor, or single-agent ARB) and a beta blocker.
  • Each patient should take only ONE angiotensin system blocker at a time. If patient has a contraindication for all types of angiotensin system blockers [eg, due to hyperkalemia], then hydralazine plus nitrate is an alternative therapy.
  • The decision to initiate ARNI depends upon factors including the patient's continuing access to medication and concerns (in the judgement of the clinician) regarding the potential risk of hypotension.

ACE inhibitor: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; SBP: systolic blood pressure; ARNI: angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan); K: potassium; HFrEF: heart failure with reduced ejection fraction (left ventricular ejection fraction ≤ 40%).

* For patients with hypotension and/or worsening renal function, volume status should be assessed to determine whether diuretic therapy should be reduced or held. Refer to UpToDate content on management of adverse effects of ACE inhibitors and ARBs.

¶ In this context, an example of a low-dose ACE inhibitor is lisinopril 7.5 mg daily, and an example of a low-dose ARB is valsartan 40 mg twice daily. History of angioedema (of any cause) is a contraindication for ARNI. ARNI therapy should be avoided if there is concern for hypotension in the judgement of the clinician even if the SBP criterion is met.

Δ ARNI should be initiated only if the patient will have continuous access to medication (cost of medication or copay is not prohibitive for the patient).

◊ It is reasonable to switch to ARNI in a patient with an ACE inhibitor-related cough, with the understanding that the risk of ARNI-related cough in patients with prior ACE inhibitor-related cough is unknown.

§ The last dose of ACE inhibitor should precede the first dose of ARNI (sacubitril/valsartan) by at least 36 hours due to the risk of angioedema with concurrent therapy.

¥ ACE inhibitor-related cough usually begins 1 to 2 weeks after instituting therapy but can be delayed up to 6 months. In a patient with an ACE inhibitor-related cough, it is reasonable to try ARNI, although data on the risk of ARNI-related cough in this setting is unknown.

‡ The patient should be warned that angioedema may recur weeks after discontinuation of the ACE inhibitor. Despite prior concerns about a potential risk of angioedema with ARB therapy, an association between ARB therapy and angioedema has not been found.

† After discontinuation of ACE inhibitor, ACE inhibitor-related cough typically resolves within 1 week but can persist up to 4 weeks.

** A patient who develops hypotension with ACE inhibitor or ARB despite a euvolemic status may be at risk for developing hypotension with hydralazine plus nitrate therapy.
Graphic 122401 Version 2.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟